Literature DB >> 15319250

Trends in cancer mortality in the European Union and accession countries, 1980-2000.

F Levi1, F Lucchini, E Negri, W Zatonski, P Boyle, C La Vecchia.   

Abstract

Cancer mortality rates and trends over the period 1980-2000 for accession countries to the European Union (EU) in May 2004, which include a total of 75 million inhabitants, were abstracted from the World Health Organization (WHO) database, together with, for comparative purposes, those of the current EU. Total cancer mortality for men was 166/100,000 in the EU, but ranged between 195 (Lithuania) and 269/100,000 (Hungary) in central and eastern European accession countries. This excess related to most cancer sites, including lung and other tobacco-related neoplasms, but also stomach, intestines and liver, and a few neoplasms amenable to treatment, such as testis, Hodgkin's disease and leukaemias. Overall cancer mortality for women was 95/100,000 in the EU, and ranged between 100 and 110/100,000 in several central and eastern European countries, and up to 120/100,000 in the Czech Republic and 138/100,000 in Hungary. The latter two countries had a substantial excess in female mortality for lung cancer, but also for several other sites. Furthermore, for stomach and especially (cervix) uteri, female rates were substantially higher in central and eastern European accession countries. Over the last two decades, trends in mortality were systematically less favourable in accession countries than in the EU. Most of the unfavourable patterns and trends in cancer mortality in accession countries are due to recognised, and hence potentially avoidable, causes of cancer, including tobacco, alcohol, dietary habits, pollution and hepatitis B, plus inadequate screening, diagnosis and treatment. Consequently, the application of available knowledge on cancer prevention, diagnosis and treatment may substantially reduce the disadvantage now registered in the cancer mortality of central and eastern European accession countries.

Entities:  

Mesh:

Year:  2004        PMID: 15319250     DOI: 10.1093/annonc/mdh346

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  10 in total

1.  Social will for tobacco control among the Hungarian public health workforce.

Authors:  Kristie L Foley; Péter Balázs
Journal:  Cent Eur J Public Health       Date:  2010-03       Impact factor: 1.163

2.  Central and Eastern European experience with sunitinib in metastatic renal cell carcinoma: a sub-analysis of the global expanded-access trial.

Authors:  Eduard Vrdoljak; Lajos Géczi; Jozef Mardiak; Tudor-Eliade Ciuleanu; Sophie Leyman; Ke Zhang; Peter Sajben; Laszlo Torday
Journal:  Pathol Oncol Res       Date:  2015-01-04       Impact factor: 3.201

Review 3.  Causal role of Helicobacter pylori infection in gastric cancer: an Asian enigma.

Authors:  Kartar Singh; Uday C Ghoshal
Journal:  World J Gastroenterol       Date:  2006-03-07       Impact factor: 5.742

4.  Cancer epidemiology in Central, South and Eastern European countries.

Authors:  Eduard Vrdoljak; Marek Z Wojtukiewicz; Tadeusz Pienkowski; Gyorgy Bodoky; Peter Berzinec; Jindrich Finek; Vladimir Todorović; Nenad Borojević; Adina Croitoru
Journal:  Croat Med J       Date:  2011-08-15       Impact factor: 1.351

Review 5.  A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs.

Authors:  A Carrato; A Falcone; M Ducreux; J W Valle; A Parnaby; K Djazouli; K Alnwick-Allu; A Hutchings; C Palaska; I Parthenaki
Journal:  J Gastrointest Cancer       Date:  2015-09

6.  Trends in corrected lung cancer mortality rates in Brazil and regions.

Authors:  Deborah Carvalho Malta; Daisy Maria Xavier de Abreu; Lenildo de Moura; Gustavo C Lana; Gulnar Azevedo; Elisabeth França
Journal:  Rev Saude Publica       Date:  2016-06-27       Impact factor: 2.106

7.  Impact of stage, management and recurrence on survival rates in laryngeal cancer.

Authors:  Jesper Brandstorp-Boesen; Ragnhild Sørum Falk; Morten Boysen; Kjell Brøndbo
Journal:  PLoS One       Date:  2017-07-14       Impact factor: 3.240

8.  MicroRNA-128 targeting RPN2 inhibits cell proliferation and migration through the Akt-p53-cyclin pathway in colorectal cancer cells.

Authors:  Taicheng Zhou; Lili Wu; Qirui Wang; Zhipeng Jiang; Yingru Li; Ning Ma; Wenhao Chen; Zehui Hou; Wenchang Gan; Shuang Chen
Journal:  Oncol Lett       Date:  2018-09-26       Impact factor: 2.967

9.  Gender-related hormonal risk factors for oral cancer.

Authors:  Zsuzsanna Suba
Journal:  Pathol Oncol Res       Date:  2007-10-07       Impact factor: 2.874

10.  Dose-dense adjuvant chemotherapy for primary breast cancer.

Authors:  Monica Fornier; Larry Norton
Journal:  Breast Cancer Res       Date:  2005-02-10       Impact factor: 6.466

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.